Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.280
+0.020 (1.59%)
At close: Mar 31, 2026, 4:00 PM EDT
1.280
0.00 (0.00%)
After-hours: Mar 31, 2026, 4:00 PM EDT

Innate Pharma Balance Sheet

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
28.0966.470.6184.23103.76
Short-Term Investments
6.2214.3721.8517.2616.08
Cash & Short-Term Investments
34.3180.7792.46101.49119.84
Cash Growth
-57.52%-12.64%-8.90%-15.31%-20.97%
Accounts Receivable
12.44.9755.5638.3518.42
Total Current Assets
46.7185.74148.01139.83138.26
Net Property, Plant & Equipment
4.365.136.328.5410.17
Other Intangible Assets
--0.421.5644.19
Long-Term Investments
10.4610.289.835.1239.88
Other Long-Term Assets
1.29.910.6422.8235
Total Assets
62.72111.06175.19207.86267.5
Accounts Payable
15.0416.0117.0220.9128.57
Current Portion of Leases
8.88.718.942.130.75
Unearned Revenue
9.338.0613.5116.7819.92
Other Current Liabilities
3.480.210.171.540.65
Total Current Liabilities
36.6532.9839.6441.3479.89
Long-Term Leases
13.7722.2930.9640.1513.5
Other Long-Term Liabilities
3446.9652.6972.2366.67
Total Long-Term Liabilities
47.7769.2483.65112.3780.17
Total Liabilities
84.42102.23123.29153.71160.06
Common Stock
4.694.194.044.013.98
Additional Paid-in Capital
408.03390.98384.26379.64375.22
Accumulated Other Comprehensive Income
1.120.030.50.820.46
Retained Earnings
-435.54-386.36-336.89-330.32-272.21
Shareholders' Equity
-21.78.8351.954.15107.44
Total Liabilities & Equity
62.72111.06175.19207.86267.5
Total Debt
22.573139.8942.2544.25
Net Cash (Debt)
11.7449.7852.5659.2375.59
Net Cash Growth
-76.42%-5.30%-11.26%-21.63%-42.98%
Net Cash Per Share
0.130.610.650.740.95
Book Value
-21.78.8351.954.15107.44
Book Value Per Share
-0.240.110.650.681.35
Tangible Book Value
-21.78.8351.4952.663.25
Tangible Book Value Per Share
-0.240.110.640.660.80
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q